It’s not just obesity. Drugs like Ozempic will change the world
As they become cheaper, they promise to improve billions of lives
Every day seems to bring more exciting news. First the drugs tackled diabetes. Then, with just an injection a week, they took on obesity. Now they are being found to treat cardiovascular and kidney disease, and are being tested for Alzheimer’s and addiction. It is early days yet, but glp-1 receptor agonists have all the makings of one of the most successful classes of drugs in history. As they become cheaper and easier to use, they promise to dramatically improve the lives of more than a billion people—with profound consequences for industry, the economy and society.
This article appeared in the Leaders section of the print edition under the headline “The everything drugs ”
From the October 26th 2024 edition
Discover stories from this section and more in the list of contents
Explore the edition
A fantastic start for Friedrich Merz
The incoming chancellor signals massive increases in defence and infrastructure spending
The lesson from Trump’s Ukrainian weapons freeze
And the grim choice facing Volodymyr Zelensky
Western leaders must seize the moment to make Europe safe
As they meet in London, Vladimir Putin will sense weakness
Prabowo Subianto takes a chainsaw to Indonesia’s budget
The result? More money for the president’s boondoggles
Inheriting is becoming nearly as important as working
More wealth means more money for baby-boomers to pass on. That is dangerous for capitalism and society
Donald Trump has begun a mafia-like struggle for global power
But the new rules do not suit America